Comparison · NCT02545907-8f145a22
Dose Level 0- Safety Population vs Dose Level 1- Safety Population: Compliance Profile of KTD Based on Reported Chemotherapy Compliance Data.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dose Level 0- Safety Population vs Dose Level 1- Safety Population: Compliance Profile of KTD Based on Reported Chemotherapy Compliance Data. Trial comparisons, record NCT02545907-8f145a22. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02545907-8f145a22
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.333 | 0.0615 | 0.792 | wilson | |
| Risk in group 2 | 0.714 | 0.359 | 0.918 | wilson | |
| Risk difference, group 1 minus group 2 | -0.381 | -0.721 | 0.2 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.467 | 0.0881 | 2.47 | log | |
| Odds ratio, group 1 over group 2 | 0.2 | 0.0109 | 3.66 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dose Level 0- Safety Population than on Dose Level 1- Safety Population | 2.62 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dose Level 0- Safety Population | All patients allocated to dose level 0 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set. | 1 | 3 | OG000 |
| Group 2 | Dose Level 1- Safety Population | All patients allocated to dose level 1 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set. | 5 | 7 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Compliance Profile of KTD Based on Reported Chemotherapy Compliance Data.
- Description
The compliant profile of participants to KTD will be assessed by determining the number of missed doses from recorded data. Participants will be regarded as compliant if participants have missed no more than 14 days of thalidomide, 2 days of dexamethasone, and 1 dose of carfilzomib per cycle. Compliance will be reported in terms of the number of participants who were compliant.
- Time frame
- Within 6 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- NCT number
- NCT02545907
- Phases
- PHASE1, PHASE2
- Conditions
- Amyloidosis
- Interventions
- Carfilzomib, Thalidomide, Dexamethasone
- Lead sponsor
- University College, London
- Results first posted
- 2021-04-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02545907?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02545907-8f145a22